- Conditions
- Head and Neck Cancer
- Interventions
- Bevacizumab, Erlotinib, Paclitaxel, 5-FU, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 7
- States / cities
- Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 12,515
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Cancer
- Interventions
- fluorouracil, gemcitabine hydrochloride, radiation therapy
- Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 77
- States / cities
- Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- PI3K inhibitor BKM120, pemetrexed disodium, carboplatin, laboratory biomarker analysis, pharmacological study, quality-of-life assessment
- Drug · Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Uterine Corpus Leiomyosarcoma
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases
- Interventions
- ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB
- Drug
- Lead sponsor
- Nancy Lin, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Lymphoma
- Interventions
- filgrastim, pegfilgrastim, rituximab, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, liposomal cytarabine, methotrexate, therapeutic hydrocortisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 13
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
- Conditions
- HIV, Tuberculosis
- Interventions
- Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
- Conditions
- Colon Cancer, Colorectal Cancer, Colorectal Carcinoma, Colon Disease
- Interventions
- Pembrolizumab, Ibrutinib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
- Interventions
- PF-08046876, Pembrolizumab, Cisplatin, Carboplatin
- Drug · Combination Product
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 21
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 11 more
- Conditions
- HIV-1-infection
- Interventions
- TMB-365/TMB-380
- Drug
- Lead sponsor
- TaiMed Biologics Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 3 more
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Ketamine, Midazolam
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Tourette Syndrome
- Interventions
- Dronabinol and Palmitoylethanolamide
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Postoperative Pain
- Interventions
- Clonidine, Ropivacaine
- Drug
- Lead sponsor
- Mihaela Visoiu
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- abaloparatide, abaloparatide solid microstructured transdermal system
- Combination Product
- Lead sponsor
- Radius Health, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years · Female only
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Glendale, Arizona + 65 more
- Conditions
- Myelofibrosis
- Interventions
- Imetelstat sodium, Ruxolitinib
- Drug
- Lead sponsor
- Geron Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 6
- States / cities
- Duarte, California • Irvine, California • Coral Gables, Florida + 3 more
- Conditions
- Neoplasms, Breast
- Interventions
- pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg, pazopanib (GW786034) 800 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 19
- States / cities
- Jonesboro, Arkansas • Alhambra, California • Bakersfield, California + 16 more
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
- Interventions
- 5-FU, Leucovorin, Liposomal Irinotecan, Paricalcitol, Serum and plasma blood samples, Tumor biopsy
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Papillomatosis, HIV Infections
- Interventions
- Interferon-alpha, placebo
- Drug · Other
- Lead sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 12
- States / cities
- San Francisco, California • Fort Lauderdale, Florida • Augusta, Georgia + 9 more
- Conditions
- Prostatic Neoplasms
- Interventions
- CP-751,871, docetaxel, prednisone
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New York, New York • Cleveland, Ohio + 2 more
- Conditions
- Eustachian Tube Dysfunction, Facial Pain
- Interventions
- SinuSonic Device
- Device
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Improved Appearance of the Banana Roll Region
- Interventions
- CoolSculpting Elite combined with CoolTone Treatments, CoolSculpting Elite
- Device
- Lead sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
- Other
- Eligibility
- 22 Years to 65 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
- Interventions
- VG161, Nivolumab Injection [Opdivo]
- Drug
- Lead sponsor
- Virogin Biotech Canada Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel
- Combination Product · Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 26
- States / cities
- Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 23 more
- Conditions
- Metastatic Triple Negative Breast Cancer
- Interventions
- Combination of Veliparib + Lapatinib
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama